Rezum

How to get reimbursed for BPH water vapor ablation
Water vapor ablation yields positive results at 2 yearsTreatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.
Convective water vapor ablation successful at 2 yearsA treatment system that uses steam to ablate prostate tissue (Rezūm, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
Convective transurethral therapy reduces LUTSA handheld transurethral therapy that delivers targeted sterile water vapor reduces lower urinary tract symptom severity in patients with BPH with no impact on sexual function.
New tech may bring exciting era in BPHThe management of BPH has had an interesting roller coaster ride over the past 25 years with new medicines, minimally invasive surgical therapies, and a host of novel surgical technologies, including lasers and bipolar electrosurgery.
Urology Product Preview: Oral testosterone agent outperforms gel in hypogonadism studyDrugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.
Best of AUA 2014: BPH/LUTSRichard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.
Convective heat system shows efficacy in treating BPHAnalyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.
Urology Product Preview November 2013Urology drugs and devices in the pipeline from AltheRx Pharmaceuticals, TARIS Biomedical, AstraZeneca, NxThera, NovaBay Pharmaceuticals, and OncoGenex Pharmaceuticals.